Form 8-K - Current report:
SEC Accession No. 0001213900-23-019289
Filing Date
2023-03-10
Accepted
2023-03-10 17:30:05
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea175048-8k_actinium.htm   iXBRL 8-K 22659
  Complete submission text file 0001213900-23-019289.txt   195649

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE atnm-20230310.xsd EX-101.SCH 3245
3 XBRL LABEL FILE atnm-20230310_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE atnm-20230310_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT ea175048-8k_actinium_htm.xml XML 3612
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 23724991
SIC: 2834 Pharmaceutical Preparations